Introduction {#Sec1}
============

The aquaporins (AQPs) constitute a family of integral channel proteins that facilitate the osmotically driven bidirectional water transport across the cell membrane \[[@CR2], [@CR54]\]. Previous studies identified at least 13 mammalian members, widely expressed in various fluid-transporting epithelial and endothelial cells. AQP1, AQP2, AQP4, AQP5 and AQP8 are chiefly water selective, while AQP3, AQP7, AQP9 and AQP10 transport glycerol in addition to water. Among AQP family members, AQP1, AQP4 and AQP9 are expressed in the central nervous system (CNS) \[[@CR2], [@CR54]\]. AQP1, initially identified in red blood cells and renal proximal tubular epithelium, is expressed constitutively in the apical surface of choroid plexus epithelium in the CNS \[[@CR8], [@CR39]\]. The crystal structure of AQP1 water channel is composed of a dumbbell-shaped homotetramer of 28-kDa subunits, each of which contains six transmembrane domains and an extracellular epitope that defines the Colton blood group antigen on erythrocyte membranes \[[@CR10]\]. Outside the brain, AQP1 is expressed in retinal amacrine cells \[[@CR24]\], Schwann cells \[[@CR14]\], dorsal root ganglia neurons \[[@CR48]\], lungs and hepatobiliary epithelium. AQP1-null individuals negative for the Colton antigen, having homozygous mutations in the AQP1 gene exhibit a defect in urinary concentration and reduced pulmonary vascular permeability after overloading fluid \[[@CR27], [@CR28]\]. AQP1-null mice show a decrease in cerebrospinal fluid (CSF) production, indicating a pivotal role of AQP1 in CSF secretion in the CNS \[[@CR42]\]. Although AQP1 is expressed widely in vascular endothelial cells outside the CNS, the levels of AQP1 expression are very low in brain endothelial cells, and no expression is found in cultured rodent astrocytes \[[@CR12]\].

Earlier studies showed that high-grade astrocytoma cells intensely express both AQP1 and AQP4, suggesting the involvement of water channel upregulation in development of tumor-associated brain edema \[[@CR41], [@CR45]\]. AQP1-null mice show a reduction in tumor vascularity and migratory capacity \[[@CR46]\]. In contrast, overexpression of AQP1 in fibroblast in culture accelerates anchorage-independent cell growth characteristic of malignant transformation \[[@CR19]\]. Mouse melanoma cells, overexpressing AQP1 show an increase in metastatic potential \[[@CR21]\]. AQP1 plays a central role in macrophage and leukocyte recruitment during acute inflammation \[[@CR40]\]. Based on these observations, it is proposed that AQP1 regulates cell growth and migration by a mechanism that involves cytoskeletal reorganization, triggered by water transport at the leading edge of proliferating and migrating cells \[[@CR54]\]. Furthermore, AQP1 plays a role in apoptotic cell shrinkage by regulating the cell volume \[[@CR22]\].

Increasing evidence indicates that astrocytes express AQP1 in CNS under pathological conditions. The expression of both AQP1 and AQP4 is enhanced markedly in reactive astrocytes accumulating in the lesions of subarachnoid hemorrhage \[[@CR4]\], contusion \[[@CR51]\], Creutzfeldt-Jakob disease (CJD) \[[@CR44]\], cerebral infarction \[[@CR47]\], and multiple sclerosis (MS) \[[@CR47]\]. However, the precise mechanism accounting for upregulation of AQP1 in reactive astrocytes remains unknown. A recent study showed that the expression of AQP1 but not that of AQP4 is augmented in cortical astrocytes at the early stage of Alzheimer disease (AD), suggesting a pathological role of abnormal regulation of water transport in AD \[[@CR43]\]. Because intracerebral accumulation of amyloid-β (Aβ) plays a central role in the pathogenesis of AD \[[@CR16]\], and activated astrocytes are often associated with Aβ plaques in AD brains \[[@CR37], [@CR55]\], we investigated the possible relationship between Aβ deposition and AQP1 expression in astrocytes in the cerebral cortex of AD.

Materials and methods {#Sec2}
=====================

Human brain tissues {#Sec3}
-------------------

Ten micron-thick serial sections were prepared from autopsied brains of 11 AD patients composed of five men and six women with the mean age of 71 ± 9 years and 16 other neurological disease (non-AD) patients composed of nine men and seven women with the mean age of 67 **±** 12 years. The non-AD cases include three patients with Parkinson disease (PD), three with multiple system atrophy (MSA), four with amyotrophic lateral sclerosis (ALS), three with myotonic dystrophy, one with spinal and bulbar muscular atrophy (SBMA), one with schizophrenia, and one with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS). The average of brain weight was 1,038 ± 163 g in AD cases and 1,220 ± 173 g in non-AD cases. Brain tissues of the motor cortex and hippocampus were fixed with 4% paraformaldehyde (PFA) and embedded in paraffin. In the present study, we tentatively defined the hippocampus and parahippocampal cortex as the hippocampus. All AD cases were satisfied with the Consortium to Establish a Registry for Alzheimer's disease (CERAD) criteria for diagnosis of definite AD \[[@CR34]\]. They were categorized into stage C of amyloid deposition and stage VI of neurofibrillary degeneration, following the Braak's staging \[[@CR9]\]. The autopsied brain samples were obtained from Research Resource Network (RRN), Japan. Written informed consent was obtained from all the cases examined. The Ethics Committee of National Center of Neurology and Psychiatry approved the present study.

Human astrocytes in culture {#Sec4}
---------------------------

Human astrocytes were established from neuronal progenitor (NP) cells isolated from a human fetal brain (BioWhittaker-Cambrex, Walkersville, MD, USA). NP cells plated on a polyethyleneimine-coated surface were incubated in DMEM/F-12 medium (Invitrogen, Carlsbad, CA, USA) containing an insulin-transferrin-selenium (ITS) supplement (Invitrogen), 20 ng/ml recombinant human EGF (Higeta, Tokyo, Japan), 20 ng/ml recombinant human bFGF (PeproTech EC, London, UK), and 10 ng/ml recombinant human LIF (Chemicon, Temecula, CA, USA). For the induction of astrocyte differentiation, NP cells were incubated for several weeks in DMEM (Invitrogen) supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin and 100 μg/ml streptomycin (feeding medium). The inclusion of FBS in the culture medium induced vigorous proliferation and differentiation of astrocytes accompanied by a rapid reduction in non-astroglial cells. The purity of astrocytes exceeded 98% by GFAP immunolabeling, as described previously \[[@CR47]\].

To determine the effects of stress-inducing stimuli on AQP1 expression, human astrocytes were incubated for 48 h in the feeding medium with inclusion of 10 μM human Aβ~1-40~ peptide (Peptide Institute, Osaka, Japan), 10 μM human Aβ~1-42~ peptide (Peptide Institute), 100 mM NaCl, 100 μM sodium nitroprusside, a NO donor (SNP; Merck-Calbiochem, Tokyo, Japan), 10 μM *all trans* retinoic acid (RA; Sigma, St Louis, MO, USA), 100 nM phorbol 12-myristate 13-acetate (PMA; Sigma), 1 mM dibutyryl cyclic AMP (dbcAMP; Sigma), 10 μM MG-132, a proteasome inhibitor (Merck-Calbiochem), or 1 μM thapsigargin, an endoplasmic reticulum (ER) stress inducer (TG; Sigma), or incubated in the serum-free DMEM/F-12 medium containing 100 μM hydrogen peroxide.

Double-labeling immunohistochemistry {#Sec5}
------------------------------------

After deparaffination, tissue sections were heated in 10 mM citrate sodium buffer, pH 6.0 by autoclave at 125°C for 30 s in a temperature-controlled pressure chamber (Dako, Tokyo, Japan). For Aβ immunolabeling, tissue sections were pretreated with formic acid for 5 min at room temperature (RT). All tissue sections were incubated with phosphate-buffered saline (PBS) containing 10% normal goat serum (NGS) at RT for 15 min to block non-specific staining. Then, tissue sections were initially stained at 4°C overnight with primary antibodies listed in Table [1](#Tab1){ref-type="table"}, followed by incubation with alkaline phosphatase (AP)-conjugated secondary antibody (Nichirei), and colorized with New Fuchsin substrate. The specificity of anti-AQP1 antibody (H-55, Santa Cruz Biotechnology, Santa Cruz, CA, USA) and anti-AQP4 antibody (H-80, Santa Cruz Biotechnology) was verified by Western blot analysis of HEK293 cells that express the transgene of human AQP1 or AQP4 as described previously \[[@CR47]\]. In addition, we found that choroid plexus epithelial cells, representing a positive control cell type, were stained intensely by H-55 (Supplementary Fig. 1). After inactivation of the antibody by autoclaving the sections at 125°C for 30 s in 10 mM citrate sodium buffer, pH 6.0 following the manufacturer's instruction (Nichirei), they were treated for 15 min with 3% hydrogen peroxide-containing distilled water to block the endogenous peroxidase activity. Then, they were relabeled with different primary antibodies listed in Table [1](#Tab1){ref-type="table"}, followed by incubation with horseradish peroxidase (HRP)-conjugated secondary antibody (Nichirei), and colorized with DAB substrate and counterstained with hematoxylin. For negative controls, the step of incubation with primary antibodies was omitted.Table 1Primary antibodies utilized for immunochemistry and Western blot analysisAntibodies (Name)SuppliersCodeOriginImmunogensAntigen specificityConcentration used for immunohistochemistryConcentration used for Western blottingAQP1 (H-55)Santa Cruz Biotechnologysc-20810RabbitA peptide covering amino acid residues 215--269 of human AQP1AQP1800 ng/ml200 ng/mlAQP1 (1/22)Santa Cruz Biotechnologysc-32727MouseA peptide covering amino acid residues 249--269 of rat AQP1AQP14 μg/mlNAAQP4 (H-80)Santa Cruz Biotechnologysc-20812RabbitA peptide covering amino acid residues 244--323 mapping at the C-terminus of human AQP4AQP4800 ng/mlNAAβ~11-28~ (12B2)Immunobiological Laboratory10027MouseHuman amyloid beta 11--28 peptideAβ~1-40~, Aβ~1-42~, Aβ~1-43~1 μg/mlNAGFAP (GA5)Nichirei422261MousePurified swine spinal cord GFAPGFAPPredilutedNACD68 (KP1)DakoN1577MouseLysosomal granules of human lung macrophagesCD68PredilutedNAFactor VIII (F8/86)Nichirei412191MouseHuman factor VIII-related antigenFactor VIII-related antigenPredilutedNANSENichirei422081RabbitPurified bovine brain NSENSEPredilutedNAACTB (AC-15)SigmaA1978MouseA synthetic peptide mimicking the N-terminus of beta-actinbeta-ActinNA500 ng/mlXpressInvitrogenR910-25MouseXpress epitope sequenceXpress6 μg/ml240 ng/ml*AQP1* aquaporin-1, *AQP4* aquaporin-4, *Aβ* amyloid-beta, *GFAP* glial fibrillary acidic protein, *NSE* neuron-specific enolase, *ACTB* beta-actin, *NA* not applied

In the motor cortex and hippocampus of each case, the number of Aβ^+^AQP1^+^ plaques, Aβ^−^AQP1^+^ spots, and Aβ^+^AQP1^−^ plaques with size exceeding the diameter of 50 μm was counted in ten random fields at 400× microscopic magnification on the Olympus BX51 universal microscope. The average of percentages of Aβ^+^AQP1^+^ plaques, Aβ^−^AQP1^+^ spots, and Aβ^+^AQP1^−^ plaques, the average of numbers of Aβ-immunoreactive plaques, and the average of numbers of AQP1-immunoreactive plaques/spots were compared between AD and non-AD cases by statistical analysis with a Mann--Whitney's *U* test. The *P* value of \<0.05 was considered as significant.

Immunocytochemistry {#Sec6}
-------------------

For immunocytochemistry, the cells on cover glasses were fixed with 4% PFA in 0.1 M phosphate buffer, pH 7.4 at RT for 5 min, followed by incubation with PBS containing 0.5% Triton X-100 at RT for 3 min. After blocking non-specific staining by PBS containing 10% NGS, the cells were incubated at RT for 30 min with a mixture of anti-GFAP antibody GA5 and anti-AQP1 antibody H-55. Then, they were incubated at RT for 30 min with a mixture of Alexa Fluor 568-conjugated anti-mouse IgG (Invitrogen) and Alexa Fluor 488-conjugated anti-rabbit IgG (Invitrogen). After several washes, they were mounted with an anti-fade reagent containing 4′, 6′-diamidino-2-phenylindole (DAPI) (Invitrogen), and examined on the Olympus BX51 universal microscope. Negative controls were processed following all the steps, except for exposure to anti-AQP1 antibody.

Western blot analysis {#Sec7}
---------------------

To prepare total protein extract, the cells were homogenized in RIPA lysis buffer, composed of 50 mM Tris--HCl, pH 7.5, 150 mM NaCl, 1% Nonidet P40, 0.5% sodium deoxycholate, 0.1% SDS, and a cocktail of protease inhibitors (Sigma), followed by centrifugation at 12,000 rpm for 10 min at RT. The supernatant was collected, solved in the lysis buffer containing 2.5 M urea, and separated on a 12% SDS-PAGE gel \[[@CR47]\]. The protein concentration was determined by a Bradford assay kit (BioRad, Hercules, CA, USA). After gel electrophoresis, the protein was transferred onto nitrocellulose membranes, and immunolabeled at RT overnight with anti-AQP1 antibody H-55. Then, the membranes were incubated at RT for 30 min with HRP-conjugated anti-rabbit IgG (Santa Cruz Biotechnology). The specific reaction was visualized by exposing to a chemiluminescent substrate (Pierce, Rockford, IL, USA). After the antibodies were stripped by incubating the membranes at 50°C for 30 min in stripping buffer, composed of 62.5 mM Tris--HCl, pH 6.7, 2% SDS and 100 mM 2-mercaptoethanol, the membranes were processed for relabeling with mouse monoclonal anti-β-actin antibody AC-15 (Sigma).

Immunoprecipitation analysis {#Sec8}
----------------------------

To determine the molecular interaction between Aβ and AQP1, the N-terminal half of AQP1, including the transmembrane helices H1, H2 and H3 (amino acid residues 2-132; NTF), the C-terminal half of AQP1, including the transmembrane helices H4, H5 and H6 (amino acid residues 133--269; CTF) \[[@CR10], [@CR32]\] (GenBank accession No. NM_198098), and the C-terminal fragment β (amino acid residues 597--695; CTFβ) of amyloid precursor protein (APP) (NM_201414) were amplified by PCR using PfuTurbo DNA polymerase (Stratagene, La Jolla, CA, USA) and the sense and antisense primer sets following: 5′ccgaattccggccagcgagttcaagaagaag3′ and 5′for the NTF of AQP1, 5'cggaattccggtgaactcgggccagggcct3′ and 5′cggggtaccccgctatttgggcttcatctccac3′ for the CTF of AQP1, and 5′and 5'cgggatcccgctagttctgcatctgctcaaagaa3′ for the CTFβ of APP. After digestion with *Eco*RI, *Kpn*I, *Xba*I or *Bam*HI (New England BioLabs, Beverly, MA, USA), the PCR products were cloned in the expression vectors pCMV-Myc (Clontech, Mountain View, CA, USA) or p3XFLAG-CMV7.1 (Sigma) to express a fusion protein with an N-terminal Flag or Myc tag. At 48 h after co-transfection of the vectors, HEK293 cells were homogenized in M-PER lysis buffer (Pierce) supplemented with a cocktail of protease inhibitors. After preclearance, the supernatant was incubated at 4°C overnight with mouse monoclonal anti-Flag M2 affinity gel (Sigma), rabbit polyclonal anti-Myc antibody-conjugated agarose (Sigma), or the same amount of normal mouse or rabbit IgG-conjugated agarose (Santa Cruz Biotechnology). After several washes, the immunoprecipitates were processed for Western blot with rabbit polyclonal anti-Myc antibody (Sigma) and mouse monoclonal anti-FLAG M2 antibody (Sigma).

Cell imaging analysis {#Sec9}
---------------------

The open reading frame (ORF) of the genes encoding AQP1 (amino acid residues 2--269) and the CTFβ or Aβ~1-42~ of APP were amplified by PCR using PfuTurbo DNA polymerase and the sense and antisense primer sets following: 5′gccagcgagttcaagaagaagctc3′ and 5′ctatttgggcttcatctccaccct3′for AQP1, 5′and 5'cgggatcccgctagttctgcatctgctcaaagaa3′ for the CTFβ of APP, and 5′ cgggatcccgctacgctatgacaacaccgcccac3′ for Aβ~1-42~. After digestion with *Eco*RI, *Kpn*I, *Xho*I or *Bam*HI, the PCR products were cloned in the expression vectors pDsRed-Express-C1 (Clontech) or pcDNA3.1/NT/GFP-TOPO (Invitrogen) to express a fusion protein with an N-terminal DsRed or GFP tag. At 24--48 h after co-transfection of the vectors, HEK293 cells were fixed briefly in 4% PFA and mounted with the anti-fade reagent containing DAPI.

Tissue protein overlay analysis {#Sec10}
-------------------------------

To identify AQP1-binding targets in brain tissues in situ, we prepared recombinant human AQP1 protein tagged with Xpress (AQP1-Xpress), serving as a probe for tissue protein overlay. The ORF of AQP1 gene amplified by PCR described above was cloned into a prokaryotic expression vector pTrcHis-TOPO (Invitrogen), expressed in *E. coli*, and purified to obtain a fusion protein having an N-terminal Xpress tag. After deparaffination, tissue sections were heated in 10 mM citrate sodium buffer, pH 6.0 by autoclave at 125°C for 30 s. They were treated with formic acid and 3% hydrogen peroxide, and then incubated at 4°C overnight with AQP1-Xpress at the concentration of 167 μg/ml or with the same amount of recombinant β-galactosidase fragment tagged with Xpress (LacZ-Xpress), serving as a negative control. After washing with PBS, the tissue sections were incubated at RT for 45 min with anti-Xpress antibody, followed by incubation with HRP-conjugated secondary antibody, and colorized with DAB substrate. After inactivation of the antibodies by autoclaving, the tissue sections were processed for immunolabeling with anti-Aβ antibody, followed by incubation with AP-conjugated secondary antibody, and colorized with New Fuchsin substrate.

Results {#Sec11}
=======

The close association of AQP1-expressing astrocytes with Aβ deposition in the cerebral cortex of AD {#Sec12}
---------------------------------------------------------------------------------------------------

First, we studied AQP1 and AQP4 expression in the motor cortex and hippocampus of 11 AD cases and 16 age-matched other neurological disease (non-AD) cases by double-labeling immunohistochemistry with a combination of anti-AQP1 antibody, anti-AQP4 antibody, anti-Aβ antibody, and antibodies against cell type-specific markers. In all cases, examined, AQP1 was expressed exclusively in multipolar fibrillary astrocytes with highly-branched processes that often surround blood vessels and neurons (Figs. [1](#Fig1){ref-type="fig"}a, b, d--f, [2](#Fig2){ref-type="fig"}a, c--e). Neither NSE^+^ neurons nor CD68^+^ microglia nor factor VIII-related antigen-positive vascular endothelial cells were immunolabeled with AQP1 antibody (Figs. [1](#Fig1){ref-type="fig"}e, f, [2](#Fig2){ref-type="fig"}a). Approximately 70% of AQP1^+^ multipolar fibrillary cells coexpressed an intense GFAP immunoreactivity, verifying that they represent a subpopulation of astrocytes with a unique morphology (Fig. [1](#Fig1){ref-type="fig"}d). Importantly, AQP1-expressing astrocytes were either often located on the top of or in close proximity to Aβ plaques in the motor cortex and hippocampus of AD, but rarely in non-AD cases (Fig. [1](#Fig1){ref-type="fig"}a).Fig. 1Multipolar fibrillary astrocytes express AQP1 in the cerebral cortex of AD. The tissue sections of the motor cortex of AD patients were processed for double-labeling immunohistochemistry using a panel of antibodies listed in Table [1](#Tab1){ref-type="table"}. **a--c** AQP1 (*brown*) and Aβ (*red*), **d** AQP1 (*red*) and GFAP (*brown*), **e** AQP1 (*brown*) and CD68 (*red*), and **f** AQP1 (*brown*) and factor VIII-related antigen (*red*). Multipolar fibrillary astrocytes expressing an intense AQP1 immunoreactivity are often located on the top of Aβ deposition (**a**)Fig. 2Multipolar fibrillary astrocytes express AQP1 and AQP4 in the cerebral cortex of AD and other neurological diseases. The tissue sections of the motor cortex and the hippocampus of the patients with AD, Parkinson disease (PD), and amyotrophic lateral sclerosis (ALS) were processed for double-labeling immunohistochemistry using a panel of antibodies listed in Table [1](#Tab1){ref-type="table"}. **a** the motor cortex of the patient with AD; AQP1 (*red*) and NSE (*brown*), **b** the hippocampus of the patient with AD; AQP4 (*brown*) and Aβ (*red*), **c** the hippocampus of the patient with ALS; AQP1 (*red*) and AQP4 (*brown*), and **d--f** the motor cortex of the patient with PD; AQP1 (*brown*) and Aβ (*red*). Three distinct populations of astrocytes, AQP1^+^AQP4^+^ (*thick arrow*), AQP1^+^AQP4^−^ (*arrowhead*), and AQP1^−^AQP4^+^ (*thin arrows*), are identified (**c**)

In contrast, AQP4 immunoreactivity was distributed more diffusely in the whole neuropil, gliotic and perivascular lesions, and the pia matter in the cerebral cortex of both AD and non-AD cases, although the staining was more intense in AD brains (Fig. [2](#Fig2){ref-type="fig"}b; Supplementary Fig. 2). In all the cases, multipolar fibrillary astrocytes expressing an intense immunoreactivity for AQP4 were less prominently found,when compared with AQP1-expressing astrocytes. Double labeling identified three distinct populations of astrocytes, AQP1^+^AQP4^+^, AQP1^+^AQP4^−^, and AQP1^−^AQP4^+^, suggesting that AQP1 and AQP4 might play an overlapping but non-redundant role in astrocytic water channel function (Fig. [2](#Fig2){ref-type="fig"}c). AQP1^+^AQP4^+^ cells consisted of approximately 15% of all AQP-immunoreactive cells. Owing to the diffuse distribution of intense neuropil staining of AQP4, we could not clearly discriminate AQP4-immunoreactive astrocytes with or without a contact with Aβ, making it highly difficult to count exactly the number of AQP4-expressing astrocytes located in the proximity to Aβ plaques.

Next, tissue sections of the motor cortex and hippocampus of AD and non-AD patients were processed for double-labeling immunohistochemistry with a combination of anti-AQP1 antibody and anti-Aβ antibody. Then, we counted the number of Aβ^+^AQP1^+^ plaques (Figs. [1](#Fig1){ref-type="fig"}a, [2](#Fig2){ref-type="fig"}d), Aβ^−^AQP1^+^ spots (Figs. [1](#Fig1){ref-type="fig"}b, [2](#Fig2){ref-type="fig"}e), and Aβ^+^AQP1^−^ plaques (Figs. [1](#Fig1){ref-type="fig"}c, [2](#Fig2){ref-type="fig"}f) with the size exceeding the diameter of 50 μm, by random scanning of the cerebral cortex at a 400× magnification under microscope (Fig. [3](#Fig3){ref-type="fig"}a, b). The average of percentages of Aβ^+^AQP1^+^ plaques was significantly greater in both the motor cortex and hippocampus of AD than that of non-AD (*P* = 1.092E-05 in the motor cortex; *P* = 1.410E-05 in the hippocampus). In contrast, the average of percentages of Aβ^−^AQP1^+^ spots was significantly greater in both the motor cortex and hippocampus of non-AD than that of AD (*P* = 1.865E-05 in the motor cortex; *P* = 5.035E-04 in the hippocampus). By counting of ten random high magnification fields, the average of total number of Aβ-immunoreactive plaques or AQP1-immunoreactive plaques/spots larger than 50 μM diameter was 16.2 ± 4.7 for Aβ and 16.3 ± 4.4 for AQP1 in the motor cortex of AD, and 15.1 ± 4.1 for Aβ and 16.5 ± 4.0 for AQP1 in the hippocampus of AD. In contrast, it was 0.6 ± 1.9 for Aβ and 2.7 ± 1.8 for AQP1 in the motor cortex of non-AD, and 2.6 ± 4.5 for Aβ and 8.6 ± 6.1 for AQP1 in the hippocampus of non-AD. Thus, the average number of Aβ-immunoreactive plaques and AQP1-immunoreactive plaques/spots, was elevated significantly in the cerebral cortex of AD compared with non-AD (*P* = 1.217E-05 for Aβ in the motor cortex; *P* = 6.416E-05 for Aβ in the hippocampus; *P* = 1.092E-05 for AQP1 in the motor cortex; and *P* = 0.003 for AQP1 in the hippocampus). All of these observations suggest a close association of AQP1 with Aβ deposition in the cerebral cortex of AD. Alternatively, the possibility should be considered that the population of Aβ ^+^AQP1^+^ plaques is much smaller in non-AD brains, because there existed less amounts of Aβ deposition and smaller numbers of AQP1-immunoreactive astrocytes in the brains of non-AD cases. In this setting, Aβ deposition might not be obligatory for induction of the astrocytic expression of AQP1.Fig. 3The number of AQP1 and Aβ-immunoreactive plaques in the cerebral cortex of AD. The tissue sections of the motor cortex and the hippocampus of 11 AD patients and 16 age-matched non-AD patients were processed for double-labeling immunohistochemistry with anti-AQP1 antibody H-55 and anti-Aβ antibody 12B2. The number of Aβ^+^AQP1^+^ plaques, Aβ^+^AQP1^−^ plaques, and Aβ^−^AQP1^+^ spots with the size exceeding the diameter of 50 μm was counted by random scanning of the cerebral cortex at a 400× magnification under microscope. The percentage of immunoreactive plaques/spots, Aβ^+^AQP1^+^, Aβ ^+^AQP1^−^ or Aβ^−^AQP1^+^, per the total was calculated, and the average is shown as the *bar* with standard deviation. **a** Motor cortex. **b** Hippocampus. \**P *= 1.092E-05, \*\**P* = 1.865E-05, \*\*\* *P* = 1.410E-05, and \*\*\*\**P* = 5.035E-04

The expression and induction of AQP1 in cultured human astrocytes {#Sec13}
-----------------------------------------------------------------

Since a subset of astrocytes intensely expressed AQP1 in AD and non-AD brains, in the next step, we investigated AQP1 expression in cultured human astrocytes. Consistent with high levels of AQP1 mRNA expression in cultured human astrocytes, as we reported previously \[[@CR47]\], virtually all of them expressed constitutively a discernible immunoreactivity for AQP1, located mostly on the plasma membrane and less abundantly in the cytoplasm (Fig. [4](#Fig4){ref-type="fig"}a--d). The expression of AQP1 in astrocytes was further validated by Western blot. Cultured human astrocytes expressed constitutively a substantial amount of AQP1 protein with a molecular weight of 28-kDa, which represents the non-glycosylated form (Fig. [5](#Fig5){ref-type="fig"}a, lanes 1, 4, 6). They did not consistently express the glycosylated form with a larger molecular weight (data not shown). Then, cultured human astrocytes were exposed for 48 h to various stimuli that potentially affect the levels of AQP1 expression. The levels of AQP1 protein expression were not affected by treatment with either Aβ~1-42~ or Aβ~1-40~ peptide, but elevated markedly by exposure to 100 mM NaCl, modestly by 10 μM MG-132, and reduced substantially by treatment with 100 nM phorbol 12-myristate 13-acetate (PMA) (Fig. [5](#Fig5){ref-type="fig"}, panel a, lanes 2, 3, 5, 10, 12). Upregulation by NaCl and downregulation by PMA were verified by real-time RT-PCR analysis (Supplementary Fig. 3). In contrast, the treatment with either sodium nitroprusside (SNP), hydrogen peroxide, retinoic acid (RA), dibutyryl cyclic AMP (dbcAMP), or thapsigargin (TG) did not affect the levels of AQP1 protein expression (Fig. [5](#Fig5){ref-type="fig"} lanes 7, 8, 9, 11, 13). These results suggest that human astrocytes that express substantial amounts of AQP1 protein under the baseline culture condition are fairly resistant to induction of AQP1 by non-osmotic stimuli.Fig. 4Cultured human astrocytes express AQP1 immunoreactivity. Cultured human astrocytes were processed for triple-labeling immunocytochemistry with anti-AQP1 antibody H-55, anti-GFAP antibody GA5, and DAPI. **a** AQP1, lower magnification; **b** AQP1, higher magnification; **c** GFAP, and **d** merge of **b** and **c** with DAPIFig. 5AQP1 protein levels in cultured human astrocytes exposed to various stimuli. Cultured human astrocytes were exposed for 48 h to the stimuli, and then processed for Western blot analysis with anti-AQP1 antibody H-55. The identical blot was relabeled with anti-β-actin antibody AC-15. The *panels* consist of three distinct sets of experiments, composed of the set \#1 (*lanes1*--*3*), the set \#2 (*lanes4* and *5*), and the set \#3 (*lanes6*--*13*). The *lanes* (*1*--*13*) represent (1, 4, 6) untreated or vehicle-treated cells, (2) 10 μM Aβ~1-40~ peptide, (3) 10 μM Aβ~1-42~ peptide, (5) 100 mM NaCl, (7) 100 μM sodium nitroprusside, (8) 100 μM hydrogen peroxide, (9) 10 μM *all trans* retinoic acid, (10) 100 nM phorbol 12-myristate 13-acetate, (11) 1 mM dibutyryl cyclic AMP, (12) 10 μM MG-132, and (13) 1 μM thapsigargin. Twenty-five microgram of protein was loaded on each lane. The expression levels indicate the ratio of AQP1 protein level of treated cells versus untreated cells, which were standardized against β-actin protein level

Molecular interaction of AQP1 and CTFβ of APP {#Sec14}
---------------------------------------------

Finally, the molecular interaction between AQP1 and Aβ was investigated by immunprecipitation of recombinant fusion proteins with distinct epitope tags coexpressed in HEK293 cells, followed by pull down with tag-specific antibodies. Since preliminary experiments suggested that the segment spanning Aβ~1-42~ alone is not enough to identify the protein--protein interaction owing to its small size (4 kDa) on a conventional Tris-glycine SDS-PAGE gel, we have chosen the CTFβ of APP, spanning both Aβ and the APP intracellular domain (AICD), expressed as a Flag-tagged fusion protein. Alternatively, either the NTF or the CTF of AQP1 was expressed as a Myc-tagged fusion protein. Pull-down assay showed that the CTFβ of APP interacts with the NTF of AQP1, but not with the CTF of AQP1, indicating that the molecular interaction is not attributable to an artifact caused by overexpression in HEK293 cells (Fig. [6](#Fig6){ref-type="fig"}a, b, upper and lower panels; lane 2).Fig. 6Molecular interaction of AQP1 and the CTFβ of APP. **a**, **b** Immunoprecipitation (IP) analysis. The C-terminal fragment-beta (CTFβ) of amyloid precursor protein (APP) was expressed as a Flag-tagged fusion protein, while either the NTF or the CTF of AQP1 was expressed as a Myc-tagged fusion protein. They were coexpressed in HEK293 cells, and processed for pull-down with anti-Flag or anti-Myc antibody, followed by Western blot reciprocally with anti-Myc or anti-Flag antibody. **a** The interaction between CTFβ and NTF of AQP1. **b** The interaction between CFTβ and CTF of AQP1. The *lanes* (*1*--*3*) represent (1) input control of cell lysate, (2) IP with anti-tag antibodies, and (3) IP with normal mouse or rabbit IgG. **c** Cell imaging analysis. Either the CTFβ or Aβ ~-42~ was expressed as a DsRed-tagged fusion protein, while the full-length AQP1 was expressed as a GFP-tagged fusion protein. They were coexpressed in HEK293 cells. *a* AQP1 with a GFP fluorescence, *b* CTFβ with a DsRed fluorescence, *c* merge of *a* and *b* with DAPI, *d* AQP1 with a GFP fluorescence, *e* Aβ~1-42~ with a DsRed fluorescence, and *f* merge of *d* and *e* with DAPI

To obtain additional evidence to support the results of immunoprecipitation analysis, we conducted cell imaging analysis. Either the CTFβ or Aβ~1-42~ was expressed as a DsRed-tagged fusion protein, while the full-length AQP1 was expressed as a GFP-tagged fusion protein. The CTFβ of APP, as well as Aβ~1-42~, was located chiefly in the cytoplasm, while AQP1 was expressed mainly on the plasma membrane, and none of them were expressed in the nucleus, when overexpressed in HEK 293 cells. A discernible GFP fluorescence was also detected in the cytoplasm, where AQP1 was found to be colocalized with CTFβ of APP and Aβ~1-42~ (Fig. [6](#Fig6){ref-type="fig"}c, panels a--f).

To determine the in vivo molecular interaction between AQP1 and Aβ, we performed tissue protein overlay analysis using recombinant human AQP1 protein spanning the entire ORF tagged with Xpress (AQP1-Xpress) that enables us to identify the expression of AQP1-binding proteins in situ. This probe was recognized by both anti-AQP1 antibody and anti-Xpress antibody (Fig. [7](#Fig7){ref-type="fig"}a, panels a and b; lane 2). By tissue protein overlay, the AQP1-Xpress probe did not decorate the entire surface of Aβ-immunoreactive plaques, but the core of the plaques often expressed a nodular or irregular-shaped AQP1-Xpress-immunoreactivity (Fig. [7](#Fig7){ref-type="fig"}b, panel a). The AQP1-Xpress probe also reacted intensely with many neurons, neuropil, and microglia in AD brains, suggesting that these cells and constituents might express the molecules with AQP1-binding epitopes (Fig. [7](#Fig7){ref-type="fig"}b, panel a). The AQP1-Xpress probe did not label multipolar fibrillary astrocytes. In contrast, the LacZ-Xpress probe did not react with neurons, microglia, astrocytes, or Aβ plaques, excluding non-specific interaction via the Xpress epitope of recombinant proteins (Fig. [7](#Fig7){ref-type="fig"}b, panel b).Fig. 7Tissue protein overlay analysis with recombinant AQP1 protein as a probe. **a** Western blot of recombinant proteins. The identical blot was labeled sequentially with *a* anti-Xpress antibody or *b* anti-AQP1 antibody H-55. **b** Tissue protein overlay. The tissue sections of the motor cortex of AD were incubated with *a* AQP1-Xpress or *b* LacZ-Xpress. Then, they were processed for immunolabeling with anti-Xpress antibody. After inactivation of the antibodies by autoclaving, the tissue sections were processed for relabeling with anti-Aβ antibody. Xpress (*brown*) and Aβ (*red*). The *arrows* indicate an existence of AQP1-binding molecules in the core of Aβ deposition

Discussion {#Sec15}
==========

In the present study, we investigated the relationship between Aβ deposition and astrocytic AQP1 expression in the motor cortex and hippocampus of 11 AD patients and 16 age-matched non-AD cases. We found that AQP1 was expressed exclusively in a subpopulation of multipolar fibrillary astrocytes in all cases. The great majority of AQP1-expressing astrocytes were located either on the top of or in close proximity to Aβ plaques in AD brains but not in non-AD cases, whereas AQP1-expressing astrocytes independent of Aβ deposition were found predominantly in non-AD brains. By tissue protein overlay analysis, AQP1-Xpress-immunoreactivities, reflecting the existence of the molecules with AQP1-binding epitopes, were located in the core of Aβ plaques in AD brains. A number of previous studies showed that astrocytes, keeping in touch with Aβ plaques, are activated by Aβ itself in AD brains \[[@CR37], [@CR55]\]. In line with the previous observations, we showed that AQP1-expressing multipolar fibrillary astrocytes are closely associated with Aβ deposition in AD brains. These observations suggest the hypothesis that Aβ deposition might cause abnormal brain water homeostasis by interfering with astrocytic water channel function. The present study included solely AD brains classified into the most advanced stage of the disease. To evaluate the hypothesis described above, it is important to investigate AQP1 expression in AD brains at early stages with minimal deposition or diffuse plaques of Aβ. Importantly, a recent study using Western blot and immunohistochemistry showed that the levels of AQP1 protein expression are significantly elevated in the frontal cerebral cortex of AD at the Braak's stage II, where reactive astrocytes similar to multipolar fibrillary astrocytes observed in the present study express a cell-surface punctuate AQP1 immunoreactivity \[[@CR43]\]. In contrast, no differences are found in AQP1 protein levels between the stages V--VI of AD and the age-matched control cases, suggesting the possibility that upregulated expression of AQP1 on astrocytes in AD brains is a disease stage-dependent event \[[@CR43]\].

To obtain a deeper insight into our in vivo observations of close association of AQP1-expressiong astrocytes with Aβ, we studied the molecular interaction between AQP1 and Aβ in a transient expression system of HEK293 cells in vitro. By the pull-down assay, the CTFβ of APP interacts with the N-terminal half (amino acid residues 2--132; NTF) of AQP1 spanning the transmembrane helices H1, H2, and H3, which contains one of two NPA motifs pivotal for water transport function \[[@CR2], [@CR32]\]. A recent study indicated that the amino acid residues composed of Phe 58, His 182, Cys 191, and Arg 197 are involved in constituting the constriction region of water channel, while both His 76 and Val 155 act as a valve by dynamically blocking water permeation \[[@CR49]\]. AQP1, along with the CTFβ and Aβ~1-42~, were colocalized on the cell-surface membrane and in the cytoplasm, when they were coexpressed in cultured cells. Although the primary site of AQP1 expression is the cell-surface membrane, the intracellular location of AQP1 has been reported previously. AQP1 integrates into the ER membrane, when overexpressed in HEK293 cells \[[@CR11]\]. Secretin induces a redistribution of AQP1 protein from intracellular vesicles to the plasma membrane in cholangiocytes \[[@CR33]\]. Importantly, both APP and AQP1 constitute transmembrane proteins, and Aβ and AQP1 are enriched in lipid rafts of the plasma membrane \[[@CR7], [@CR52]\], raising the possibility of a direct protein--protein interaction between Aβ and AQP1 at cell-to-cell contact interfaces in situ.

However, it should be kept in mind that the binding of AQP1 to Aβ in vitro does not always precisely reflect the in vivo situation of the interaction between AQP1-expressing astrocytes and Aβ. Importantly, both reactive astrocytes and activated microglia express scavenger receptors that mediate the clearance of extracellularly-deposited fibrillar Aβ \[[@CR1]\]. Therefore, it is meaningful to study in the next step the molecular interaction of AQP1 and fibrillar Aβ, and its physiological interference with water transport in an astrocyte culture model in vitro. Although the present study, in the absence of high-resolution immunoelectron microscopic analysis dose not provide definitive evidence to show the direct interaction between Aβ and AQP1 in vivo, we could currently propose two different working models of the molecular interaction of AQP1 and Aβ; (1) astrocytic AQP1 could interact with extracellular deposition of fibrillary Aβ (Fig. [8](#Fig8){ref-type="fig"}a) and (2) astrocytic AQP1 could interact with the Aβ and/or AICD transmembrane/intracellular segment of endogenous APP (Fig. [8](#Fig8){ref-type="fig"}b).Fig. 8Working models of the molecular interaction between AQP1 and Aβ. AQP1 is composed of a homotetramer of 28-kDa subunits. Each monomeric subunit contains six transmembrane helices (H1--H6) with two hemipores with an Asparagine--Proline--Alanine (NPA) motif, which fold to form a water channel (see the reference \[[@CR32]\]). Pull-down assay suggested that the CTFβ of APP, composed of Aβ and AICD, interacts with the N-terminal half of AQP1 spanning H1, H2, and H3. Two different working models could be proposed for the molecular interaction of AQP1 and Aβ; **a** astrocytic AQP1 could interact with extracellular deposition of fibrillary Aβ, and **b** astrocytic AQP1 could interact with the Aβ and/or AICD transmembrane/intracellular segment of endogenous APP

Regulatory mechanisms underlying AQP1 expression are highly complex. Systemic hyponatremia elevates the levels of expression of AQP1 on choroid plexus epithelial cells \[[@CR35]\]. Thyroid transcription factor-1 (TTF1), expressed in choroids plexus epithelium, facilitates CSF production by enhancing AQP1 gene expression \[[@CR25]\]. Hypertonic stress induces the expression of AQP1 in rodent renal medullary cells by activating extracellular signal-regulated kinase (ERK), p38 MAP kinase, and c-Jun N-terminal kinase (JNK), all of which regulate a hypertonicity-responsive element (HRE) located in the AQP1 promoter \[[@CR53]\]. Acetazolamide inhibits the osmotic water permeability by reducing AQP1 protein expression \[[@CR56]\]. Treatment with corticosteroids increases the levels of AQP1 protein expression in the capillary endothelium of the peritoneal membrane and the lung \[[@CR26], [@CR50]\]. AQP1 expression is induced in rat gliosarcoma cells by exposure to hypoxia, dexamethasone, and PDGF, and by incubating the cells in hypertonic culture media containing NaCl, [d]{.smallcaps}-glucose or fructose \[[@CR17]\]. Treatment with proteasome inhibitors elevates the levels of AQP1 protein expression in mouse fibroblasts \[[@CR29]\]. All of these observations suggest that distinct promoter elements are activated in response to osmotic and non-osmotic stimuli in different cell types. We found that AQP1 expression in cultured human astrocytes is upregulated markedly by hypertonic sodium chloride, modestly by MG-132, and downregulated by PMA, an activator of protein kinase C (PKC). It is worthy to note that tetradecanoylphorbol 13-acetate (TPA), another activator of PKC, induces a rapid decrease in AQP4 mRNA in rat astrocytes in culture \[[@CR38]\].

The pathophysiological role of AQP1-expressing multipolar fibrillary astrocytes in AD brains remains unknown. Increasing evidence indicate that AQP1 acts as a gas transporter, such as O~2~, CO~2~, and NO \[[@CR6], [@CR13], [@CR18]\]. AQP1, by transporting NO out of endothelial cells and into vascular smooth muscle cells, plays a pivotal role in endothelium-dependent vasorelaxation \[[@CR18]\]. AQP1 expression is markedly upregulated in rat lungs by hypoxia \[[@CR13]\]. AQP1 is required for hypoxia-inducible angiogenesis in human retinal vascular endothelial cells \[[@CR23]\]. We showed previously that AQP1-expressing astrocytes accumulate in ischemic lesions of cerebral infarction and active demyelinating lesions of MS \[[@CR47]\]. Because the production of NO and reactive nitrogen species (RNS), as well as reactive oxygen species (ROS), is markedly enhanced in the brains of ischemia, MS and AD \[[@CR3]\], the possibility exists that AQP1-expressing astrocytes with a great migratory capacity \[[@CR54]\] act as a scavenger of RNS and ROS by patrolling the cortex of AD. However, treatment with SNP and hydrogen peroxide did not affect the levels of AQP1 protein expression in human astrocytes in culture, suggesting that these stimuli do not directly upregulate AQP1 expression in astrocytes.

We found that the levels of AQP1 protein expression on cultured human astrocytes were not affected by exposure to Aβ~1-42~ peptide at least within a 48 h-observation period, although we observed a drastic change in morphology of astrocytes, exhibiting the morphology with ruffled cell-surface membranes (Supplementary Fig. 4). The molecular basis for this change remains unknown. Even though Aβ desposition does not act as a potent inducer for AQP1 expression in cortical astrocytes in AD brains, the close association of AQP1 with Aβ suggests that extensive Aβ deposition could cause abnormal brain water homeostasis by interfering with astrocytic water channel function. Supporting this view, previous clinical studies showed that brain ion and water homeostasis is profoundly disturbed in AD \[[@CR5], [@CR20]\]. Recent studies have indicated that intracerebral accumulation of not only Aβ oligomers but also that of the APP intracellular domain (AICD) affects the gene expression involved in neuronal survival \[[@CR36]\]. Human astrocytes produce Aβ in response to TGFβ, suggesting that astrocytes might coexpress Aβ, along with AQP1, when activated by cytokines in AD brains \[[@CR30]\]. The great majority of APP holoprotein is located in intracellular membranous compartments in cultured astrocytes \[[@CR15]\]. AQP1 is produced initially as a precursor protein with four transmembrane segment-spanning topology at the ER membrane, and following topological reorientation it is processed to form a mature protein with six transmembrane segment-spanning topology at the plasma mambrane \[[@CR31]\]. After overexpression of the transgenes without signal peptide sequences in HEK 293 cells, the CTFβ of APP, as well as that of Aβ~1-42~, was located chiefly in the cytoplasm, while AQP1 was expressed mainly on the plasma membrane and less abundantly in the cytoplasm. Although the overexpression experiments in HEK293 cells do not precisely reflect the physiological situation, a discernible colocalization was detected in the cytoplasm, not excluding the interaction in intracellular membranous compartments. The pull-down assay showed that the CTFβ, composed of both Aβ and AICD, interacts directly with the NTF of AQP1, although these observations did not specify the AQP1-interacting domain of APP, either Aβ or AICD, or both. Therefore, the possible scenario could be raised that astrocytic Aβ and/or AICD segment of endogenous APP interacts with AQP1 either on the plasma membrane or at specific intracellular membrane compartments (Fig. [8](#Fig8){ref-type="fig"}b). In addition, the hypothetical view could be proposed that Aβ and AICD, by binding to AQP1, not only affect water permeability, but also modulate signaling pathways in astrocytes essential for supporting neuronal survival in the brains of AD.

In conclusion, AQP1-expressing fibrillary astrocytes, which represent a unique subset of astrocytes, might have a close association with Aβ in the brains of advanced stages of AD, although there exists no definitive evidence to show the direct contact. However, these observations suggest the working hypothesis that Aβ deposition could cause abnormal brain water homeostasis by interfering with astrocytic water channel function. Further studies, including the immunohistochemical analysis of various disease stages, high-resolution morphological analysis, and cell physiological analysis, are required to evaluate this hypothesis.
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Supplementary Fig. 1. Choroid plexus epithelial cells express AQP1. The tissue sections of the hippocampus of a patient with AD were processed for double-labeling immunohistochemistry with anti-AQP1 antibody (H-55, brown) and anti-Aβ antibody (12B2, red) (PPT 1447 kb)
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Supplementary Fig. 2. Perivascular astrocytes express AQP4. The tissue sections of the hippocampus of a patient with AD were processed for double-labeling immunohistochemistry with anti-AQP4 antibody (H-80, brown) and anti-Aβ antibody (12B2, red) (PPT 1065 kb)
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Supplementary Fig. 3. Real-time RT-PCR analysis of AQP1 mRNA expression in cultured human astrocytes. Cultured human astrocytes were untreated (CNT) or exposed for 48 hours to 100 mM NaCl or 100 nM phorbol 12-myristate 13-acetate (PMA). They were then processed for real-time RT-PCR analysis by using the AQP1-specific primer set. The levels of AQP1 mRNA were standardized against those of the glyceraldehyde-3-phosphate dehydrogenase (G3PDH) gene detected in the identical cDNA samples (PPT 49 kb)
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Supplementary Fig. 4. Morphology of cultured human astrocytes exposed to Aβ~1-42~ peptide. Cultured human astrocytes were exposed for 48 hours to (a) the vehicle (dimethylsulfoxide), (b) 10 μM Aβ~1-40~ peptide, or (c) 10 μM Aβ~1-42~ peptide. Phase-contrast photomicrographs. Also see the footnote of Fig. 5 (PPT 3075 kb)
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